A public offering of 2.75 million shares of common stock has brought in $79.3 million in gross proceeds for Accelerate Diagnostics. Net proceeds from the offering, which included a 30-day option for underwriters to buy up to 412,500 additional shares, will be used to support commercialization efforts and general corporate functions.
Public offering pulls in $79.3M for Accelerate Diagnostics
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.